Differential Ligand Binding Affinities of Human Estrogen Receptor-α Isoforms

Amanda H. Y. Lin, Rachel W. S. Li, Eva Y. W. Ho, George P. H. Leung, Susan W. S. Leung, Paul M. Vanhoutte, Ricky Y. K. Man*

Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR

Abstract

Rapid non-genomic effects of 17β-estradiol are elicited by the activation of different estrogen receptor-α isoforms. Presence of surface binding sites for estrogen have been identified in cells transfected with full-length estrogen receptor-α66 (ER66) and the truncated isoforms, estrogen receptor-α46 (ER46) and estrogen receptor-α36 (ER36). However, the binding affinities of the membrane estrogen receptors (mERs) remain unknown due to the difficulty of developing of stable mER-transfected cell lines with sufficient mER density, which has largely hampered biochemical binding studies. The present study utilized cell-free expression systems to determine the binding affinities of 17β-estradiol to mERs, and the relationship among palmitoylation, membrane insertion and binding affinities. Saturation binding assays of human mERs revealed that [3H]-17β-estradiol bound ER66 and ER46 with KD values of 68.81 and 60.72 pM, respectively, whereas ER36 displayed no specific binding within the tested concentration range. Inhibition of palmitoylation or removal of the nanolipoprotein particles, used as membrane substitute, reduced the binding affinities of ER66 and ER46 to 17β-estradiol. Moreover, ER66 and ER46 bound differentially with some estrogen receptor agonists and antagonists, and phytoestrogens. In particular, the classical estrogen receptor antagonist, ICI 182,780, had a higher affinity for ER66 than ER46. In summary, the present study defines the binding affinities for human estrogen receptor-α isoforms, and demonstrates that ER66 and ER46 show characteristics of mERs. The present data also indicates that palmitoylation and membrane insertion of mERs are important for proper receptor conformation allowing 17β-estradiol binding. The differential binding of ER66 and ER46 with certain compounds substantiates the prospect of developing mER-selective drugs.

Introduction

Rapid non-genomic actions of estrogen are physiologically significant in our biological systems including the cardiovascular, nervous and skeletal systems [1,2]. Short incubation of 17β-estradiol (the major active form of estrogen) rapidly triggers the formation of intracellular signaling molecules such as cAMP [3,4], cGMP [5] and calcium [6], leading to rapid cellular responses by activation of subsequent signaling pathways, such as protein kinase A, protein kinase C and extracellular regulated kinase (ERK) [2,7]. For example, physiological concentrations of 17β-estradiol enhanced endothelium-dependent relaxations induced by acetylcholine in the rat aorta [8]. This response is mediated by activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and endothelial nitric oxide synthase (eNOS) and is regulated by a non-receptor tyrosine kinase c-Src [9–11]. This type of rapid (within seconds to a few minutes) response to estrogen is non-genomic, since it does not involve gene transcription and protein synthesis [12].

The estrogen receptors (ER), ERα and ERβ, are well recognized as nuclear steroid receptors that interact with specific DNA sequences, namely estrogen responsive elements (ERE), to regulate gene expression in response to estrogen [13]. The existence of membrane estrogen receptors (mERs), responsible for the non-genomic actions of estrogen, was first indicated by the presence of specific surface binding sites for estrogen conjugated with cell-impermeable albumin [14]. Immunological studies using anti-ERα and ERβ antibodies have detected ERs in both nuclear and cell membrane fractions of cells endogenously expressing or transfected with ERα or ERβ [15,16]. Endothelial cells from ERα and ERβ homozygous double knock-out mice lose the ability to mediate rapid estrogen signaling, and ERα and ERβ are not expressed in either nuclear and cell membrane fractions of these animals [17]. Membrane and nuclear cell fractions of ERα-transfected CHO cells bind estrogen with similar affinities, but the membrane receptor number of ER66 was estimated to be only about 3% of the total nuclear receptor density [16]. These data show that ERα and ERβ or their isoforms are essential in rapid estrogen signaling, and also suggest that the putative mER is a homologue of the classical nuclear estrogen receptor-α, also named estrogen receptor-α66 (ER66) in view of its molecular weight. Two truncated splice variants of the ERα, 46 kDa estrogen receptor (ER46) [18] and 36 kDa estrogen receptor (ER36) [19] have been identified as mERs. To our knowledge, molecular identities of membrane isoforms of another estrogen receptor homologue, ERβ, have not yet been reported.
Functions of mERs are dependent on palmitoylation and membrane localization. Translocation of ER66 to plasma membrane as mER is achieved by interaction with the scaffolding protein of caveolae, caveolin-1 [20]. This interaction of ER66 with caveolin-1 is palmitoylation-dependent. Point mutation of Cys447 residue of ER66 to Ala impairs ER66 palmitoylation and membrane localization, and hence the subsequent rapid estrogen signaling pathways mediated by the membrane-localized ER66 [21,22]. The truncated splice variant, ER46, has lost the AF-1 transactivation domain, but retains domains for palmitoylation and caveolin-1 association [18,22]. Loss of the AF-1 domain has a minimal influence on the ability of ER46 to elicit non-genomic estrogenic responses, but also enhances palmitoylation over wild-type ER66 [22,23]. This suggests that a larger number of ER46 is palmitoylated and translocated to the membrane compared to ER66. In line with this suggestion, ER46 mediates estrogen-induced eNOS activation in a more efficient manner than ER66 [24]. Another splice variant of ER66, ER36, is devoid of the AF-1 and AF-2 transactivation domains and part of the ligand binding domain in the C-terminal is replaced by an unique 27 amino acid sequence [19], ER36 mediates the stimulation by 17β-estradiol of mitogen-activated protein kinase (MAPK) pathway [25]. ER36 also mobilizes intracellular calcium when acutely stimulated by 17β-estradiol [26]. Although the functional responses elicited by the mERs have been studied extensively [24,25,27,28] and surface binding sites of 17β-estradiol on plasma membrane of ER66, ER46 or ER36 expressing cells was shown by confocal microscopy [27,29], their binding affinities towards estrogen have not yet been determined. Biochemical binding studies were greatly hampered by the difficulty in developing stable mER-transfected cell line and the relatively low expression level of mER on the plasma membrane [16,30,31]. The present experiment determined the binding affinities of estrogen to human membrane isoforms of ERα, taking the advantages of cell-free expression systems. The importance of palmitoylation, translocation of mERs and membrane insertion in affecting these binding affinities was also investigated. Finally, the relative binding affinities of different mERs to various estrogen receptor agonists and antagonists, including phytoestrogens, were evaluated.

Results

ER66, ER46 and ER36 Colocalize with Plasma Membrane

Vesicular stomatitis virus glycoprotein (VSVG)-tagged ER66, ER46 and ER36 proteins were transfected to HEK293 cells with similar transfection efficiencies (Fig. 1). Anti-pan cadherin was used as plasma membrane marker. Confocal microscopy revealed that ER66 were expressed dominantly in the nuclear region but that a small percentage was expressed on the plasma membrane as shown by the colocalization with the plasma membrane marker, pan cadherin. ER46 and ER36 were expressed mainly in the cytosol and only a small portion on the plasma membrane.

Expression of mER Proteins Using Cell-free Expression Systems

Human ER66, ER46 and ER36 proteins were expressed in both eukaryotic and prokaryotic expression systems. The eukaryotic and prokaryotic expression systems are in vitro protein expression systems composed of cell lysates from rabbit reticulocyte and E. coli, respectively [32]. The rabbit reticulocyte lysate contains a large amount of heat-shock proteins, which function as molecular chaperones to ensure proper receptor folding [33]. Immunoreactive bands of molecular sizes of 66, 46 and 36 kDa were detected by anti-HisG antibody (Fig. 2), which corresponds to the molecular sizes of the His-tagged receptor proteins.

-ve ER66 ER46 ER36

Eukaryotic

-55 kDa -43 kDa -37 kDa

Prokaryotic

-55 kDa -43 kDa -37 kDa

Figure 1. Colocalization of ER66, ER46 and ER36 with plasma membrane. (A) Confocal microscopy of HEK293 cells transfected with VSVG-tagged ER66, ER46 or ER36 treated with anti-VSVG followed by Oregon Green 488 goat anti-rabbit secondary antibody (green). Plasma membrane is marked with anti-pan cadherin primary antibody followed by Texas Red goat anti-mouse antibody (red). Overlay images show colocalization of ER66, ER46 and ER36 with the plasma membrane (yellow). White arrows indicate some colocalization sites. (B) Western blot showing relative transfection efficiencies of His-tagged ER66, ER46 and ER36 in HEK293 cells using β-actin as a reference. Bands of 66, 46 and 36 kDa for ERs were detected by anti-HisG antibody and bands of 42 kDa were detected by anti-β-actin antibody. doi:10.1371/journal.pone.0063199.g001

Figure 2. Expression of ER66, ER46 and ER36 in cell free expression systems. Expression of ER66, ER46 and ER36 in eukaryotic and prokaryotic expression systems composed of cell lysates from rabbit reticulocytes or E.coli, respectively. Bands of 66, 46 and 36 kDa, corresponding for ER66, ER46 and ER36, respectively, were detected by anti-HisG antibody using Western blotting. doi:10.1371/journal.pone.0063199.g002
Serum Levels of 17β-estradiol Bind to ER66 and ER46, but not to ER36

ER66, ER46 and ER36 were expressed in the eukaryotic cell-free expression system. Saturation binding assays demonstrated that [3H]-17β-estradiol bound to ER66 and ER46 specifically with an equilibrium dissociation constant ($K_d$) of 68.8 pM and 60.7 pM, respectively, whereas ER36 showed no saturable specific binding (Fig. 3A). Scatchard plots revealed a single population of binding sites for [3H]-17β-estradiol in ER66 and ER46 (Fig. 3B).

Saturation binding assays showed that the $K_d$ values of 17β-estradiol binding for ER66 and ER46 expressed in prokaryotic system were 119.4 pM and 433.7 pM, respectively, whereas ER36 showed no saturable specific binding (Fig. 3C). Scatchard plots showed that 17β-estradiol bound to ER66 and ER46 at a single binding site (Fig. 3D). The binding affinities of 17β-estradiol to ER isoforms are summarized in Table 1.

Inhibition of Posttranslational Palmitoylation and Membrane Insertion of mERs Impaired Ligand Binding

In order to elucidate whether or not palmitoylation is involved in ligand binding of mERs, a palmitoylation inhibitor (2-bromopalmitate) was added to the transcription/translation reaction in the eukaryotic cell-free expression system. Non-palmitoylated and palmitoylated ER66 or ER46 were separated by native protein electrophoresis at neutral pH, which distinguishes proteins according to their size, shape and intrinsic charge. Upper and lower bands were detected in cell lysates expressing ER66 or ER46 (Fig. 4A). Addition of the palmitic acid group decreases the positive electric charge of ER66 and ER46. Therefore, palmitoylated ER proteins are represented by the lower bands, as proteins more negatively charged migrate faster towards the positive electrode. Treatment with 2-bromopalmitate (100 µM) abolished the expression of palmitoylated ER66 and ER46 (Fig. 4B). Inhibition of palmitoylation by 2-bromopalmitate reduced the binding affinities of ER66 and ER46 to $K_d$ values of 185 pM and 337.5 pM, respectively (Fig. 4C). Scatchard plots showed single-site binding of 17β-estradiol to ER66 and ER46 in the presence of 2-bromopalmitate (Fig. 4D).

Figure 3. ER66 and ER46, but not ER36, binds with 17β-estradiol at physiological concentrations. (A) Specific binding of [3H]-17β-estradiol to ER66 (○) and ER46 (●) expressed in eukaryotic system with $K_d$ values of 68.8 pM and 60.72 pM, respectively. No saturable specific binding was found for ER36 (□). (B) Specific binding of [3H]-17β-estradiol to ER66 (○) and ER46 (●) expressed in prokaryotic system with $K_d$ values of 119.4 pM and 433.7 pM, respectively. No saturable specific binding was found for ER36 (□). (B, D) Scatchard plot analysis for ER66 and ER46 showed single-site binding. Results are representative of three experiments each done in duplicate.

doi:10.1371/journal.pone.0063199.g003
Absence of the membrane substitute, nanolipoprotein particles (NLPs), reduced the $K_d$ values of ER66 and ER46 to 130.4 pM and 399.7 pM, respectively (Fig. 4E). Scatchard plots showed single-site binding of 17β-estradiol to ER66 and ER46 in the absence of NLPs (Fig. 4F).

### Differential Binding of ER66 and ER46 to Various Estrogen Receptor Agonists and Antagonists, and Phytoestrogens

Equilibrium binding of [3H]-17β-estradiol in the presence of various estrogen receptor agonists and antagonists, and phytoestrogens, was studied to determine the relative binding affinities (RBA) for ER66 and ER46. Monophasic curves were obtained for all the compounds tested (Fig. 5). RBA values were calculated based on the $K_{39}$ (Table 2). The overall order of affinity of the test compounds to ER66 was: PPT > raloxifene > 17β-estradiol > ICI 182,780 > MPP > genistein > tamoxifen > DPN > kaempferol > G-1 > PHTPP. ICI 182,780 had a significantly lower affinity to ER66 and ER46 than ER66. The binding affinities of estrogen receptor agonists (PPT, DPN and G-1) to ER66 were similar to those to ER46. The binding affinities of selective estrogen receptor antagonists (tamoxifen and raloxifene) to ER46 were less (by half) than those to ER66. The phytoestrogens genistein and kaempferol bound to ER46 with higher affinities when compared to ER66, but the affinities of daidzein to ER66 and ER46 were approximately the same.

### Discussion

The major findings of the present study are: (a) ER66, ER46 and ER36 colocalize with the plasma membrane; (b) 17β-estradiol binds to ER66 and ER46 with a $K_d$ value of 68.8 pM and 60.7 pM, but did not specifically bind to ER36; (c) Posttranslational palmitoylation and membrane insertion affect the binding affinities of estrogen to ER66 and ER46; and (d) ER66 and ER46 displayed differential binding affinities with various estrogen receptor agonists and antagonists, and with phytoestrogens. The present results showed that ER66, ER46 and ER36 colocalize with the plasma membrane when transfected to HEK293 cells. However, only a small proportion of ER66, ER46 and ER36 are expressed on the plasma membrane of the cells, while the receptors mainly reside in the nucleus for ER66 and the cytosol for ER46 and ER36. In preliminary studies (data not shown), stable transfection of ERs in mammalian cells results in cell toxicity [30,31]. ER-transfected cells stop growing and lyse after exposure to low estrogen concentrations. Therefore, ER-expressing cells have relatively low levels of the receptors [34], particularly the notoriously hard-to-express membrane receptors.

These difficulties in the generation of mER-expressing stable cell lines have hindered structural and biochemical studies of mERs. In the present study, a eukaryotic cell-free expression system composed of rabbit reticulocyte lysate was used. mERs were successfully expressed in a substantial amount for receptor ligand binding assays. Rabbit reticulocyte lysate has been widely used in studies of steroid binding and contains large amount of heat-shock proteins that functions as molecular chaperones to ensure proper folding of receptors [33,35]. Moreover, NLPs, nanometer-sized, discoidal particles comprising amphiphilic helical scaffold proteins that wrap themselves around the planar circumference of a lipid bilayer, were used to mimic the structure of the plasma membrane [32,36,37]. This provided an appropriate lipid bilayer plane for the attachment of ER66, ER46 and ER36.

Reference serum levels of adult female range from approximately 100 to 700 pmol/L depending on the menstrual cycle [38]. The present results demonstrate that concentrations of 17β-estradiol found in serum specifically bind to ER66 and ER46, but not to ER36. The measured $K_d$ value of ER66 (68.8 pM) is in agreement with previous reports of cytosolic ER66 which ranged from 10 pM to 1 nM [39], showing the high sensitivity and validity of the current assay. ER46 is an alternative splice variant of the ER66 transcript. It is devoid of the first 173 amino acids (A and B domain) of ER66 [18]. ER46 shares the same ligand binding domain as ER66, which may explain its similar binding affinity to 17β-estradiol. On the other hand, ER36 shares a common overall structure with ER46, except that the last 138 amino acids (part of E domain and F domain) are replaced by a unique 27 amino acid domain [19]. This unique amino acid sequence in ER36 must alter the ligand binding domain, which explains why ER36 has a much different binding affinity. Previous studies showed that ER36 binds with 17β-estradiol with a $K_d$ of 2.2 nM [26]. This concentration is much higher than physiological serum estrogen levels, which suggests that ER36 possesses functions other than solely to act as a mER. In line with this interpretation, ER36 activates the 17β-estradiol-induced MAPK pathway in ER36-transfected cells [25]. However, the MAPK pathway in these cells can also be activated to a similar level by the same concentrations of the inactive isomer of estrogen, 17α-estradiol, and by testosterone [25,28]. This illustrates that the MAPK activation in ER36-transfected cells is not specific to 17β-estradiol.

The prokaryotic expression system lacks the posttranslational modifications present in eukaryotes, and thus can be used prospectively to examine the role of such modifications of mERs in 17β-estradiol binding. ER66 and ER46 expressed in prokaryotic system had lower binding affinities to 17β-estradiol than those expressed in eukaryotic system (Table 1), suggesting that posttranslational modifications are essential to proper receptor conformation of ERs for estrogen binding. Mutational analysis on palmitoylation sites of ER66 and ER46 show that membrane

### Table 1. Summary Table of binding affinities of 17β-estradiol to mERs.

|                | $K_d$ of ER66 | $K_d$ of ER46 | $K_d$ of ER36 |
|----------------|--------------|--------------|--------------|
| Eukaryotic expression system (with NLP) | 68.8 pM | 60.7 pM | no specific binding |
| Prokaryotic expression system (with NLP) | 119.4 pM | 433.7 pM | no specific binding |
| Eukaryotic expression system (with NLP and 2-bromopalmitate) | 185.0 pM | 337.5 pM | – |
| Eukaryotic expression system (without NLP) | 130.4 pM | 399.7 pM | – |

doi:10.1371/journal.pone.0063199.t001
Differential Ligand Binding of ERα Isoforms

A

B

C

D

E

F

Key: ○ ER66 ● ER46
localization of mERs depends on palmitoylation [22,24]. 2-
Bromopalmitate was used to inhibit palmitoylation of ER66 and
ER46 expressed in eukaryotic expression system. The binding
affinities of non-palmitoylated ER66 and ER46 were reduced to
values that are similar to ER66 and ER46 expressed in prokaryotic
system. Therefore, the present data suggest that palmitoylation is
the major posttranslational modification to achieve a proper
conformation of mERs for estrogen binding.

Non-palmitoylable mERs mutant cannot associate with the
plasma membrane [22,24]. Hence, mERs expressed in eukaryotic
system in the absence of the membrane substitute, NLPs, were
used to study the significance of membrane localization. Removal
of membrane substitutes reduced the binding affinities of ER66
and ER46. This provides further evidence that membrane
localization is critical for proper estrogen binding. Only a small
portion of ER66 can be inserted in the plasma membrane in native
cells [40]. Nevertheless, the present data demonstrate that
posttranslational palmitoylation and removal of NLPs have a larger
influence on the binding affinities of ER66 (seven fold) than that of
ER66 (two fold), implying that ER46 may depend more on membrane
association to obtain correct conformation for binding and that it thus may be the predominant mER. Collectively, the present results indicate that ERs undergo postranslational palmitoylation for translocation and insertion into the plasma
membrane, and that this is crucial for proper receptor conforma-
tion for estrogen binding.

Previous in vitro studies concerning non-genomic vascular
actions of estrogen and genistein in arteries suggested differential
binding affinities of ER66 and ER46 [41,42]. Therefore, the relative binding affinities of ER66 and ER46 towards various estrogen receptor agonists and antagonists, and phytoestrogens were studied. ICI 182,780 is a steroidal estrogen receptor antagonist that competitively binds to the ER66 [43]. MPP is an antagonist which displays 200-fold selectivity for ERα over ERβ
[44], while PHTPP is a selective ERβ antagonist [45]. PPT, DPN
and G-1 are selective ERα, ERβ and G protein-coupled receptor
30 (GPR30) agonists, respectively [11,46,47]. The selective
estrogen receptor modulators, such as tamoxifen and raloxifene,
act on ERs and possess tissue-specific agonistic or antagonistic
effects [48]. Phytoestrogens, such as daidzein, genistein and kaempferol, exert non-genomic vascular effects in a similar manner as estrogen [42,49,50]. In the present study, the ligand
binding affinities of the tested compounds to ER66 were in general
similar to those to ER46, given that ER66 and ER46 have similar
binding properties. An exception is ICI 182,780, which has a 70
times lower affinity for ER66 than for ER46. The lower affinity
of ICI 182,780 for ER46 than to ER66 may account for the inability of
ICI 182,780 to inhibit the non-genomic vascular actions elicited
by estrogen and genistein in previous studies [41,42]. However,
these non-genomic vascular effects can be inhibited by MPP [42],
which has a four-fold higher affinity for ER46 when compared to
ICI 182,780. Therefore, MPP or chemical compounds with
similar structural features may used as a ER46-selective antago-
nist.

In conclusion, the present study demonstrates the binding
affinities of 17β-estradiol to human ERα isoforms. Moreover, the present results indicate that palmitoylation and membrane in-
sertion of ER66 and ER46 are important for proper receptor con-
formation for 17β-estradiol binding. Furthermore, differential binding of ER66 and ER46 with various estrogen receptor
agonists and antagonists, and phytoestrogens were observed.
Agonists that are ER46-selective are potential substitutes for
estrogen to reduce the incidence of cardiovascular diseases [51], as
they can avoid feminization in men and have lower risks in
estrogen-responsive cancers.

Materials and Methods

Chemicals

Phosphate buffered saline (PBS) was composed of 137 mM
NaCl, 2.68 mM KCl, 1.47 mM KH₂PO₄ and 8.1 mM Na₂HPO₄.
[³H]-17β-estradiol (specific activity = 110–170 Ci/mmol) was purchased from PerkinElmer (Boston, MA, USA). 17β-estradiol,
2-bromopalmitate (2-bromohexadecanoic acid), raloxifene hydro-
chloride, tamoxifen, daidzein, genistein and kaempferol were
obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). 7α,17b-
[9-4,4.5,5,5,5-Pentafluoropentyl]sulfonyl(oxononyl)estr-1,3,5(10)-triene-3,17-diol (ICI 182,780), methyl-piperidino-pyrazine dihy-
drochloride (MPP), 4-[2-phenyl-5,7-bis( trifluoro methyl)pyra-
zolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP), proplypyrazole triol (PPT), and diarylpropionitrile (DPN) were purchased from Tocris Bioscience (Ellisville, MO, USA). 1-[4-(6-bromo-benzo[1,3]dioxol-
5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-etha-
none (G-1) was bought from Cayman Chemical Co. (Ann Arbor,
MI, USA).

Cloning of Expression Vectors

Total RNA was extracted from MCF-7 cells (American Tissue
Culture Collection, Manassas, VA, USA) by TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) and then reverse transcribed to
cDNA by SuperScript first-strand synthesis system (Invitrogen)
according to manufacturer’s instructions. Full-length cDNA
transcripts of human ER α (GenBank accession no. NM_000125).
ER66 (NM_000125) and ER46 (BX640939) were synthesized by
Phy DNA polymerase (Stratagene, La Jolla, CA, USA) using forward and reverse oligonucleotide primers containing EcoRI and XhoI restriction sites, respectively (underlined). The forward primers are: 5’ GAAATTCATGACCATT-GACCCTCCACACAAA 3’ for ER66, 5’ GAATTGCGGAC-CATGGCTA TGGGAATTCGACAAAGG 3’ for ER66 and 5’ GAATTCAGGG AAGTATGGCTATGGAATCT 3’ for ER46; The reverse primers are: 5’ CTCCAGACCTGGTGGCAAGG-GAAAACC 3’ for ER66 and ER46 and 5’ ATGCAAGTCCG-GATTCTTGTTTGTGGCTCATAGTGAATACCGAGAA TTAAGCAAAAGAAT 3’ and 5’ CTGCCAGACCGAG-

Figure 4. Palmitoylation and membrane insertion is important for mER binding. (A) ER66 and ER46 proteins were analyzed by native gel
electrophoresis. Non-palmitoylated and palmitoylated ER proteins were separated as upper and lower immunoreactive bands to anti-HisG antibody
due to their difference in net electric charge imposed by the palmitic acid group in palmitoylated proteins. (B) Representative blot (upper panel) and
quantitative band intensity data (lower panel) showing the effect of 2-bromopalmitate (2-BP) treatment on the expression of palmitoylated ERs. Data
shown are the mean ± S.E. (n = 8–9) and *p < 0.05. Specific binding of [³H]-17β-estradiol to ER66 (C) and ER46 (D) expressed in eukaryotic system (C)
in the presence of 100 μM 2-BP or (E) in the absence of the membrane substitute, nanolipoprotein particles (NLPs). When expressed in the presence
of the palmitoylation inhibitor, the binding affinities of [³H]-17β-estradiol to ER66 and ER46 were reduced to 185 pM and 337.5 pM, respectively. In
the absence of NLPs, the binding affinities of [³H]-17β-estradiol to ER66 and ER46 were reduced to 130.4 pM and 399.7 pM, respectively. (D, F)
Scatchard plot analysis revealed a single population of binding sites for 17β-estradiol to both ER66 and ER46. Results are representative of three
experiments each done in duplicate.

doi:10.1371/journal.pone.0063199.g004
Figure 5. Competitive [3H]-17β-estradiol binding study of estrogenic compounds and phytoestrogens to ER66 or ER46. ER66 (○) or ER46 (●) protein was incubated with serial dilutions of non-radioactive estrogenic compounds or phytoestrogens at 4°C overnight in the presence of 100 pM [3H]-17β-estradiol. Bound and free radioligands were separated by filtration and IC_{50} values were estimated by fitting the data to a nonlinear four-parameter logistic model. Results are representative of three experiments each done in duplicate.

DOI:10.1371/journal.pone.0063199.g005
GAAC 3' for ER36. The amplified products were cleaved with EcoRI (Invitrogen) and XhoI (Invitrogen), gel purified using the Wizard Plus minipreps DNA purification system (Promega, Madison, WI, USA), and subcloned into pEXP5-NT/TOPO vector and pDNA3.1 (Invitrogen) for expression. The receptors were cloned in frame with an N-terminal polyhistidine region. All constructs were confirmed by sequencing (Invitrogen).

Co-localization Study of mERs

Expression vectors of ER66, ER46 or ER36 were transfected to HEK293 cells with Optifect reagent (Invitrogen) according to manufacturer’s instructions. Transfected cells were incubated for at least 24 hours, and then plated on coverslips one to two days prior to the experiment. Cells were fixed with methanol for ten minutes and blocked in PBS with 3% BSA for two hours. Fixed cells were then incubated with secondary antibodies, rabbit (1:160; Sigma), in PBS with 3% BSA for 1 hour at room temperature. Transfected cells were viewed under a LSM 510 META laser scanning confocal microscope (Carl Zeiss, Thornwood, NY, USA).

Cell-free Expression of mERs

Human ER66, ER46 and ER36 proteins were synthesized using a eukaryotic TnT Quick coupled transcription/translation system (Promega) composed of rabbit reticulocyte lysate with T7 RNA polymerase. The translation was initiated with incubation for 90 minutes and blocked in PBS with 3% BSA for two hours. Fixed cells were then incubated with secondary antibodies, Texas Red goat anti-mouse and Texas Red goat anti-rabbit (1:160; Sigma), in PBS with 3% BSA for 1 hour at room temperature.

Competitive Ligand Binding Assays

Receptor proteins (50 μg) were incubated with serial dilutions of [1H]-17β-estradiol in the presence or absence of a 300-fold excess of non-radioactive 17β-estradiol. All incubations were performed in glass test tubes at 3°C overnight. Bound and free radioligands were separated by filtration through a 25 mm glass microfiber GF/C filter (Whatman, Piscataway, NJ, USA) placed on a vacuum manifold (Hoefer, San Francisco, CA, USA). Filters were rapidly washed with ice-cold PBS and air-dried. Radioactivity of the filters was measured by the LS 6500 liquid scintillation counter (Beckman Coulter, Fullerton, CA, USA) after overnight incubation with ACS scintillation cocktail (Amersham, Piscataway, NJ, USA). Each assay point was run in duplicate, and the assays were repeated using two to three different batches of expressed receptor proteins. Specific binding was determined by subtracting non-specific binding (radioactivity of samples with an excess of unlabelled 17β-estradiol) from total binding. Kd were calculated as the free concentration of radioligands at half-maximal specific binding by fitting data to the Hill equation and by linear Scatchard transformation using Prism version 5.01 (GraphPad Software, La Jolla, CA, USA) [52,53].

Saturation Ligand Binding Assays

Receptor proteins (50 μg) were incubated with various concentrations (0.1 pM – 10 μM) of the test compounds. [1H]-17β-estradiol was then added (to a final concentration of 100 pM). The reaction mixture was incubated at 4°C overnight in glass test tubes. Separation of bound and free radioligands and measurement of radioactivity were performed as described above. The data were fitted in a nonlinear four-parameter logistic model to estimate the half maximal inhibitory concentration value (IC50) [54].

Relative binding affinity (RBA) of each compound tested was calculated as the ratio of IC50 value for estrogen to that compound. The RBA value for estrogen was arbitrarily set at 100.

Acknowledgments

The authors want to thank Prof. Matthias Barton and Dr. James S.K. Sham for their helpful comments and suggestions on this paper.

Author Contributions

Conceived and designed the experiments: AHYL GPHL SWSL PMV RYKM. Performed the experiments: AHYL RWSL EYWH. Analyzed the data: AHYL RWSL. Contributed reagents/materials/analysis tools: GPHL SWSL RYKM. Wrote the paper: AHYL.

Differential Ligand Binding of ERα Isoforms

Five microliter of expressed receptor proteins were incubated for 15 minutes in Laemmli buffer at 60°C and electrophoresed in a 10% SDS-PAGE gel. For native gel electrophoresis, native receptor proteins were mixed with native sample buffer and electrophoresed in a 7.5% Tris nondenaturing polyacrylamide gel (pH range 7.1 to 8.9). Proteins were transferred electrophoretically to polyvinylidene fluoride (PVDF) membranes (Bio-Rad Laboratories, Inc., Richmond, CA, USA) in a Tris-glycine transfer buffer with 20% methanol. The membranes were blocked by Tris buffered saline (TBS) containing 0.05% Tween and 5% fat-free powdered milk for 90 minutes and then incubated overnight in blocking buffer containing 1:2500 anti-HisG-HRP antibody (Invitrogen). After washing, the signal was visualized by enhanced chemiluminescence (Amersham Biosciences, Arlington Heights, IL, USA) and exposed to x-ray film.
References

1. Ho KJ, Liao JK (2002) Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 22: 1952–1961.
2. Kelly MJ, Levin ER (2001) Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12: 152–156.
3. Aronica SM, Kraus WL, Katzenellenbogen BS (1994) Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 91: 8517–8521.
4. Szejgo CM, Davis JS (1967) Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci U S A 53: 1711–1718.
5. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR (2000) Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 97: 5930–5935.
6. Tesarik J, Mendoza C (1995) Nongenomic effects of 17 beta-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J Clin Endocrinol Metab 80: 1438–1443.
7. Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4: 46–56.
8. Teoh H, Leung SW, Quan A, Huang M, Man GS, et al. (2000a) Acylcholine-mediated relaxation in rat thoracic aorta is enhanced following acute exposure to physiological concentrations of 17beta-estradiol. Mol Cell Biochem 207: 65–70.
9. Razandi M, Pedram A, Park ST, Levin ER (2003) Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701–2712.
10. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, et al. (2000) Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87: 677–682.
11. Meyer JS, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, et al. (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44: 4230–4251.
12. Simoncini T, Mannella F, Fornari L, Caruso A, Vazone G, et al. (2004) Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69: 537–542.
13. Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2935–2949.
14. Pietras RJ, Szego CM (1977) Specific binding sites for oestrogen at the outer membrane of isolated rat liver endoplasmic reticulum. Nature 276: 69–72.
15. Haynes MP, Sinha D, Russell KS, Fulton D, et al. (2000) Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87: 677–682.
16. Wenzel AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873.
17. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, et al. (2002) Antagonists selective for estrogen receptor alpha. Endocrinology 143: 941–947.
18. Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, et al. (2004) Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor-beta antagonist activity. J Med Chem 47: 5872–5893.
19. Staufler SR, Coleta CJ, Tedesco R, Nishiguchi G, Carlson K, et al. (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43: 4934–4947.
20. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn J, et al. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Biotechnol 24: 709–721.
21. Ruppel PI, Johnson MA (1998) Biopharmaceutical Statistics for Drug Development. New York: M. Dekker. 21–82.
22. Schults JR, Rappaport P, Johnson MA (1988) In: Hulme EC, editor. Receptor-ligand interactions : a practical approach. Oxford: Oxford University Press. 453–537.
23. Mukherjee S, Thalacker JS, Dey PS, Novacheck TF, Hyslop T, et al. (2004) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone and estradiol in the premenopausal, amenorrheic woman. J Clin Endocrinol Metab 89: 677–682.
24. Hall MD, Wurtman RJ, Wurtman J, Schutzberg D, Casten ED (1981) Effect of estradiol on serum luteinizing hormone in young, normal men. J Clin Endocrinol Metab 53: 1163–1167.
25. Schults JR, Rappaport P, Johnson MA (1988) Biopharmaceutical Statistics for Drug Development. New York: M. Dekker. 21–82.